Much has been published over the past 10 years regarding the influence of GB virus C (GBV-C) on HIV infection. Several studies have reported that coinfection with HIV and GBV-C leads to a more favorable outcome in patients, with a delay in the development of AIDS, compared with the outcome in patients infected with HIV alone [1] [2] [3] [4] [5] [6] . This has led some groups to look for the putative mechanism of this beneficial effect, and alterations in the cellular immune response have been implicated [7] . However, there is still considerable controversy regarding this interaction, because not all studies have shown a beneficial effect of GBV-C infection on the progression of HIV disease [8] [9] [10] [11] . By contrast, there is no debate that GBV-C plays little role, if any, in hepatitis C virus (HCV) infection, with no effect on the progression of HCV-related liver disease or on the effectiveness of interferon (IFN)-based therapy [12] [13] [14] . Similarly, there is no dispute that the course of liver disease is accelerated in patients with HCV/HIV coinfection [15] . Indeed, HCVrelated liver disease has been a significant cause of morbidity and mortality in HIVinfected patients during the era of highly active antiretroviral therapy (HAART). This has stimulated increased interest in HCV therapy in HCV/HIV-coinfected subjects, particularly given that HCV clearance rates of 140% are possible with combination pegylated (PEG)-IFN and ribavirin therapy.
What, then, do we know about the potential complex interactions among GBV-C, HCV, and HIV in triply infected subjects? For example, what effect does GBV-C have on HCV/HIV coinfection, and does clearance of GBV-C-either spontaneously or after the treatment of hepatitis C disease-affect the course of the progression of HIV disease? There is remarkably little published in this area, with the only prior report showing that patients infected with GBV-C, HCV, and HIV had an improved response to HAART [16] . In this issue of the Journal of Infectious Diseases, Schwarze-Zander et al. [17] look further into this important clinical scenario and suggest that the clearance of GBV-C during IFN-based therapy for HCV has no short-term effect on HIV control or immune status. Schwarze-Zander et al. evaluated 130 HCV/HIV-coinfected individuals as part of a larger study examining the efficacy of treatment with either PEG-IFN or non-PEG-IFN in combination with ribavirin for chronic hepatitis C infection. GBV-C RNA clearance occurred in the vast majority of HCV responders and was particularly associated with PEG-IFN plus ribavirin treatment and with patients with a higher baseline CD4 + cell count. This probably reflects the importance of the cellular immune response in viral clearance as well as the proven superior efficacy of PEG-IFN in the treatment of both HCV monoinfection and coinfection with HIV [18, 19] . Moreover, clearance of GBV-C did not seem to affect HIV load or CD4 + cell count, which suggests that, at least in the short term, immunological status was maintained. Other measures-such as the onset of AIDS and the long-term effect of GBV-C clearance on HIV markers-were not examined, which leaves unanswered the question as to whether patients who clear GBV-C are more vulnerable to the progression of HIV disease in the longer term. Importantly, the study found no beneficial effect of GBV-C infection on baseline CD4 + cell count and HIV load, adding further fuel to the debate about whether GBV-C modulates the course of HIV infection. Why, then, is there a discordance between published studies examining this issue? Several confounding factors likely contribute, at least in part, to the discrepant results, including the introduction of HAART (which could mask the effect of GBV-C), differences between study populations, and possibly even the presence of HCV. Virological factors-including GBV-C genotype and viral load-might also potentially influence HIV-related clinical outcomes. In particular, differences in GBV-C genotype distribution among different populations could affect the progression of HIV disease. GBV-C has been shown to have a worldwide distribution, with variation in the proportion of different genotypes in various populations and geographical regions, which suggests a long evolutionary history that parallels prehistoric human migration [20] . It is therefore interesting to note that the authors found GBV-C genotype 2 infection to be associated with higher CD4 + cell counts, compared with those associated with genotype 1 infection. As to why genotype 2 is associated with a higher CD4 + cell count is unclear from the study, although it is interesting to note that others have reported variations in CD4 + cell counts among patients infected with genotype 2a [21] . Certainly, clinical isolates of GBV-C are known to differ in their ability to replicate in an in vitro model, and RNA sequence variability in key regulatory regions might therefore contribute to this phenomena [22] . Clearly, these data are food for thought and should be a catalyst for further large-scale prospective studies, from separate geographical regions, to determine whether particular genotypes are associated with reduced morbidity or mortality from HIV.
Another issue highlighted in the study is the role that antibodies to the E2 envelope glycoprotein play in defining past GBV-C infection. It has been previously accepted that antibodies to the GBV-C E2 protein serve as a useful marker for diagnosing clearance of GBV-C RNA and, as such, are a useful marker of past infection [23] . However, the study indicates that none of the individuals, after receiving treatment with IFN, who went on to temporarily clear GBV-C RNA or who had sustained RNA clearance, developed E2 antibodies during the follow-up period. This is not a new phenomenon; other researchers have shown that spontaneous resolution of GBV-C is not always followed by the appearance of E2 antibodies in an HIV/GBV-C-coinfected cohort and that E2 antibodies can exist in the presence of viral RNA. Perhaps the current definition of active and past GBV-C infection should be reconsidered for some patient populations [11] . To some extent, the use of HAART, changes in drug regimens, and drug holidays, in conjunction with the patient's immune function, may contribute to these findings. The initial work with clearance of GBV-C viremia and the development of E2 antibodies was performed in healthy blood donors who had functional immune systems [24] . The findings by Schwarze-Zander et al. [17] and others [11] raise serious questions about the usefulness of E2 antibodies as a marker of past GBV-C infection in populations infected with HIV or coinfected with HIV and HCV.
GBV-C has been previously described as a virus in search of a disease [25] . Exhaustive studies by many researchers have failed to reveal any associations of GBV-C with disease [7] . Perhaps now should be the time to consider whether GBV-C plays a role in the clinical management of HIV monoinfection or HCV/HIV coinfection. Furthermore, is it clinically important to know a patient's GBV-C status and GBV-C genotype, and does knowing that information make a difference in outcome? Could differential CD4 + cell counts among certain genotypes help explain some of the differing reports regarding the beneficial influence of GBV-C on HIV? At this point, there is still not enough information to answer these questions. However, the study by Schwarze-Zander et al. takes a small step in the right direction. Still, further studies in different populations and cohorts need to be performed to examine whether the association of GBV-C genotype 2 with CD4 + cell counts is maintained and whether these novel changes translate into improved clinical outcomes for patients. In addition, longer follow-up periods may be required to fully address whether the clearance of GBV-C as a result of HCV treatment adversely affects HIV-related outcomes.
Without question, the interactions among GBV-C, HCV, and HIV are complex. All the work performed to date in triply infected individuals has focused primarily on HIV-related outcomes; however, important questions still remain. Of great importance among these questions is the role that GBV-C infection plays in the progression of liver disease in the HCV/HIV-coinfected patient. For example, does clearance of GBV-C alter the course of HCV-related liver disease? Only once these questions are addressed will we be able to begin to fully appreciate the associations between GBV-C and HCV-HIV coinfection and to understand their potential clinical impact.
